Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ibrance Illustrates Heavy FDA Workload For 'Breakthrough' Reviews

Executive Summary

Approval of Pfizer's breast cancer therapy palbociclib on the basis of Phase II data required an exhaustive set of statistical sensitivity analyses and a striking number of pre-NDA meetings.

You may also be interested in...



Pfizer’s Ibrance And The Realities Of 'Real-World' Evidence

US FDA approved expanded label for male breast cancer based on a supplement that included only non-traditional data sets. But agency is making clear that the “substantial” evidence for efficacy still came from the traditional pivotal trials – in women.

Surrogate Endpoints Only Have ‘Limited’ Evidence On Cancer Survival, Review Concludes

21st Century Cures legislation also criticized in JAMA Internal Medicine editorial.

Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability

FDA review documents for Sandoz’s filgrastim-sndz suggest that biosimilar sponsors need to consider how differences in delivery device from the reference product will play out under the 351(k) pathway, including whether new device designs and human factors data will be needed to secure interchangeability.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel